Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape ...

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...

A patient developed granulomatosis with polyangiitis (GPA), a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), following a long-standing history of systemic lupus ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus erythematosus (lupus), has been granted US FDA Fast Track designation. The ...

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Phase III results put obinutuzumab in line for approval ...